IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...
GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...
RSV-A nAbs: SCB-1019 induced GMTs in RSV-A nAbs of approximately 30,500 IU/mL, compared to approximately 26,700 IU/mL for AREXVY and approximately 3,300 IU/mL for placebo at Day 28. RSV-B nAbs: ...
“We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01 E-adjuvanted AREXVY, indicating our potential best-in-class ...
RSV neutralizing antibodies for Clover's non-adjuvanted SCB-1019 matched GSK's AS01 E-adjuvanted AREXVY in older adults, while demonstrating significantly better tolerability compared to AREXVY-- -- ...
In the ongoing Phase â… trial, 70 older adult & elderly subjects were enrolled and received either Clover's SCB-1019, GSK's AREXVY or saline placebo. Preliminary results for immunogenicity and safety ...
Last year, the FDA approved Abrysvo (Pfizer) and Arexvy (GSK) to protect seniors from serious illness, and approved Abrysvo for pregnant women in their third trimester during the RSV season ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback